P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)

• Marina Konopleva,
• Courtney D. Dinardo,
• Yan Sun,
• Sanam Loghavi,
• Paul Jung,
• Jalaja Potluri,
• Monique Dail,
• Brenda Chyla,
• Daniel A. Pollyea

Affiliations

Marina Konopleva

1 Montefiore Einstein Cancer Center, Department of Oncology, The Bronx, NY, United States

Courtney D. Dinardo

2 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, United States

Yan Sun

3 AbbVie Inc., North Chicago, IL, United States

Sanam Loghavi

4 The University of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, TX, United States

Paul Jung

3 AbbVie Inc., North Chicago, IL, United States

Jalaja Potluri

3 AbbVie Inc., North Chicago, IL, United States

Monique Dail

5 Genentech Inc, South San Francisco, CA, United States

Brenda Chyla

3 AbbVie Inc., North Chicago, IL, United States

Daniel A. Pollyea

6 School of Medicine, University of Colorado, Hematology, Aurora, CO, United States